Rare autosomal recessive disease with variable expressions. Clinical features of the disease include variable ICHTHYOSIFORM ERYTHRODERMA, CONGENITAL; bamboo hair (trichorrhexis invaginata); and ATOPIC DERMATITIS. The disease is caused by mutations in the SPINK5 gene.
Designation for several severe forms of ichthyosis, present at birth, that are characterized by hyperkeratotic scaling. Infants may be born encased in a collodion membrane which begins shedding within 24 hours. This is followed in about two weeks by persistent generalized scaling. The forms include bullous (HYPERKERATOSIS, EPIDERMOLYTIC), non-bullous (ICHTHYOSIS, LAMELLAR), wet type, and dry type.
Peptides and proteins found in BODILY SECRETIONS and BODY FLUIDS that are PROTEASE INHIBITORS. They play a role in INFLAMMATION, tissue repair and innate immunity (IMMUNITY, INNATE) by inhibiting endogenous proteinases such as those produced by LEUKOCYTES and exogenous proteases such as those produced by invading microorganisms.
Any of several generalized skin disorders characterized by dryness, roughness, and scaliness, due to hypertrophy of the stratum corneum epidermis. Most are genetic, but some are acquired, developing in association with other systemic disease or genetic syndrome.
The widespread involvement of the skin by a scaly, erythematous dermatitis occurring either as a secondary or reactive process to an underlying cutaneous disorder (e.g., atopic dermatitis, psoriasis, etc.), or as a primary or idiopathic disease. It is often associated with the loss of hair and nails, hyperkeratosis of the palms and soles, and pruritus. (From Dorland, 27th ed)
A characteristic symptom complex.
Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77).
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.
The external, nonvascular layer of the skin. It is made up, from within outward, of five layers of EPITHELIUM: (1) basal layer (stratum basale epidermidis); (2) spinous layer (stratum spinosum epidermidis); (3) granular layer (stratum granulosum epidermidis); (4) clear layer (stratum lucidum epidermidis); and (5) horny layer (stratum corneum epidermidis).
A desmosomal cadherin that is an autoantigen in the acquired skin disorder PEMPHIGUS FOLIACEUS.

Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. (1/8)

 (+info)

Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. (2/8)

 (+info)

Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. (3/8)

 (+info)

Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. (4/8)

 (+info)

Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis. (5/8)

 (+info)

When activity requires breaking up: LEKTI proteolytic activation cascade for specific proteinase inhibition. (6/8)

 (+info)

Clinical expression and new SPINK5 splicing defects in Netherton syndrome: unmasking a frequent founder synonymous mutation and unconventional intronic mutations. (7/8)

 (+info)

Ichthyosis in the newborn. (8/8)

 (+info)

Netherton Syndrome is a rare inherited genetic disorder of the skin characterized by ichthyosis, hair abnormalities, and immune system dysfunction. The condition is caused by mutations in the SPINK5 gene, which leads to defects in the production of a protein called LEKTI (Lymorphocyte Epithelial Kazal-type Related Inhibitor). This protein plays a crucial role in regulating the activity of proteases, enzymes that break down other proteins, in the skin.

The symptoms of Netherton Syndrome typically include:

1. Ichthyosis: A scaling and thickening of the skin, which can be present at birth or develop in early infancy. The scales are often generalized but may be more prominent on the extremities.
2. Hair abnormalities: Hair shafts may be fragile and break easily, leading to sparse or thin hair (bamboo hair). In some cases, there may be a complete absence of hair (alopecia).
3. Atopic dermatitis-like rash: The skin may be red and itchy, with blisters that rupture and form crusts or scales. This rash can be widespread or localized to specific areas, such as the scalp, face, and flexural surfaces.
4. Increased susceptibility to infections: Due to immune system dysfunction, individuals with Netherton Syndrome may have recurrent bacterial and viral skin infections.
5. Allergic reactions: The condition is associated with an increased risk of developing allergies, including food allergies, eczema, and asthma.
6. Growth retardation: Some individuals with Netherton Syndrome may experience growth delay and failure to thrive.
7. Developmental delays: In some cases, developmental delays or intellectual disability may be present.

The diagnosis of Netherton Syndrome is typically based on clinical features, genetic testing, and histopathological examination of skin biopsies. Treatment is primarily supportive and focuses on managing the symptoms of the condition. This may include topical treatments to moisturize and protect the skin, antibiotics to treat infections, and antihistamines to relieve itching. In some cases, systemic immunosuppressive therapy may be necessary to manage severe inflammation or allergic reactions.

Ichthyosiform erythroderma, congenital, also known as Congenital Ichthyosiform Erythroderma (CIE), is a rare inherited genetic disorder of keratinization. It is characterized by widespread scaliness and erythema (redness) that are present at birth or develop soon thereafter.

The condition is caused by mutations in various genes involved in the development of the skin barrier, leading to abnormalities in the formation and shedding of skin cells. This results in a thickened, scaly appearance of the skin, which can be associated with severe dryness, irritation, and inflammation.

The symptoms of CIE can vary widely among affected individuals, ranging from mild to severe. In addition to the characteristic skin changes, some people with CIE may also experience additional features such as ectropion (outward turning of the eyelids), eclabium (splitting of the lips), and hyperkeratosis of palms and soles.

CIE is typically a lifelong condition, and treatment is focused on managing symptoms and preventing complications. This may include the use of topical moisturizers, emollients, and keratolytic agents to help soften and remove excess skin cells. In some cases, systemic medications such as retinoids may be used to help reduce the severity of skin changes.

Secretory proteinase inhibitory proteins (SPIPs) are a group of proteins that function to regulate the activity of proteinases, which are enzymes that break down other proteins. SPIPs are produced by various cell types and secreted into extracellular spaces, where they help maintain the balance between protein degradation and synthesis.

Proteinases play crucial roles in many physiological processes, including tissue remodeling, wound healing, and immune defense. However, uncontrolled or excessive proteinase activity can lead to tissue damage and disease. SPIPs help prevent this by inhibiting the activity of specific proteinases, thereby protecting tissues from unwanted proteolysis.

Examples of SPIPs include:

1. Alpha-1 antitrypsin (AAT): A serine proteinase inhibitor that primarily inhibits neutrophil elastase and protects lung tissue from damage during inflammation.
2. Secretory leukocyte protease inhibitor (SLPI): A serine proteinase inhibitor that inhibits several proteinases, including elastase, cathepsin G, and trypsin. SLPI is produced by epithelial cells and has anti-inflammatory properties.
3. Elafin: A serine proteinase inhibitor mainly expressed in the skin and mucous membranes that inhibits neutrophil elastase, proteinase 3, and trypsin.
4. Tissue inhibitors of metalloproteinases (TIMPs): A family of proteins that inhibit matrix metalloproteinases (MMPs), which are involved in extracellular matrix remodeling.
5. Cystatins: A group of proteins that inhibit cysteine proteinases, which play a role in various physiological and pathological processes, including inflammation, immune response, and cancer.

Dysregulation of SPIPs has been implicated in several diseases, such as emphysema, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and cancer.

Ichthyosis is a group of skin disorders that are characterized by dry, thickened, scaly skin. The name "ichthyosis" comes from the Greek word "ichthys," which means fish, as the skin can have a fish-like scale appearance. These conditions can be inherited or acquired and vary in severity.

The medical definition of ichthyosis is a heterogeneous group of genetic keratinization disorders that result in dry, thickened, and scaly skin. The condition may affect any part of the body, but it most commonly appears on the extremities, scalp, and trunk. Ichthyosis can also have associated symptoms such as redness, itching, and blistering.

The severity of ichthyosis can range from mild to severe, and some forms of the condition may be life-threatening in infancy. The exact symptoms and their severity depend on the specific type of ichthyosis a person has. Treatment for ichthyosis typically involves moisturizing the skin, avoiding irritants, and using medications to help control scaling and inflammation.

Exfoliative dermatitis is a severe form of widespread inflammation of the skin (dermatitis), characterized by widespread scaling and redness, leading to the shedding of large sheets of skin. It can be caused by various factors such as drug reactions, underlying medical conditions (like lymphoma or leukemia), or extensive eczema. Treatment typically involves identifying and removing the cause, along with supportive care, such as moisturizers and medications to control inflammation and itching. In severe cases, hospitalization may be necessary for close monitoring and management of fluid and electrolyte balance.

A syndrome, in medical terms, is a set of symptoms that collectively indicate or characterize a disease, disorder, or underlying pathological process. It's essentially a collection of signs and/or symptoms that frequently occur together and can suggest a particular cause or condition, even though the exact physiological mechanisms might not be fully understood.

For example, Down syndrome is characterized by specific physical features, cognitive delays, and other developmental issues resulting from an extra copy of chromosome 21. Similarly, metabolic syndromes like diabetes mellitus type 2 involve a group of risk factors such as obesity, high blood pressure, high blood sugar, and abnormal cholesterol or triglyceride levels that collectively increase the risk of heart disease, stroke, and diabetes.

It's important to note that a syndrome is not a specific diagnosis; rather, it's a pattern of symptoms that can help guide further diagnostic evaluation and management.

Kallikreins are a group of serine proteases, which are enzymes that help to break down other proteins. They are found in various tissues and body fluids, including the pancreas, kidneys, and saliva. In the body, kallikreins play important roles in several physiological processes, such as blood pressure regulation, inflammation, and fibrinolysis (the breakdown of blood clots).

There are two main types of kallikreins: tissue kallikreins and plasma kallikreins. Tissue kallikreins are primarily involved in the activation of kininogen, a protein that leads to the production of bradykinin, a potent vasodilator that helps regulate blood pressure. Plasma kallikreins, on the other hand, play a key role in the coagulation cascade by activating factors XI and XII, which ultimately lead to the formation of a blood clot.

Abnormal levels or activity of kallikreins have been implicated in various diseases, including cancer, cardiovascular disease, and inflammatory disorders. For example, some studies suggest that certain tissue kallikreins may promote tumor growth and metastasis, while others indicate that they may have protective effects against cancer. Plasma kallikreins have also been linked to the development of thrombosis (blood clots) and inflammation in cardiovascular disease.

Overall, kallikreins are important enzymes with diverse functions in the body, and their dysregulation has been associated with various pathological conditions.

Serine proteinase inhibitors, also known as serine protease inhibitors or serpins, are a group of proteins that inhibit serine proteases, which are enzymes that cut other proteins in a process called proteolysis. Serine proteinases are important in many biological processes such as blood coagulation, fibrinolysis, inflammation and cell death. The inhibition of these enzymes by serpin proteins is an essential regulatory mechanism to maintain the balance and prevent uncontrolled proteolytic activity that can lead to diseases.

Serpins work by forming a covalent complex with their target serine proteinases, irreversibly inactivating them. The active site of serpins contains a reactive center loop (RCL) that mimics the protease's target protein sequence and acts as a bait for the enzyme. When the protease cleaves the RCL, it gets trapped within the serpin structure, leading to its inactivation.

Serpin proteinase inhibitors play crucial roles in various physiological processes, including:

1. Blood coagulation and fibrinolysis regulation: Serpins such as antithrombin, heparin cofactor II, and protease nexin-2 control the activity of enzymes involved in blood clotting and dissolution to prevent excessive or insufficient clot formation.
2. Inflammation modulation: Serpins like α1-antitrypsin, α2-macroglobulin, and C1 inhibitor regulate the activity of proteases released during inflammation, protecting tissues from damage.
3. Cell death regulation: Some serpins, such as PI-9/SERPINB9, control apoptosis (programmed cell death) by inhibiting granzyme B, a protease involved in this process.
4. Embryonic development and tissue remodeling: Serpins like plasminogen activator inhibitor-1 (PAI-1) and PAI-2 regulate the activity of enzymes involved in extracellular matrix degradation during embryonic development and tissue remodeling.
5. Neuroprotection: Serpins such as neuroserpin protect neurons from damage by inhibiting proteases released during neuroinflammation or neurodegenerative diseases.

Dysregulation of serpins has been implicated in various pathological conditions, including thrombosis, emphysema, Alzheimer's disease, and cancer. Understanding the roles of serpins in these processes may provide insights into potential therapeutic strategies for treating these diseases.

The epidermis is the outermost layer of the skin, composed mainly of stratified squamous epithelium. It forms a protective barrier that prevents water loss and inhibits the entry of microorganisms. The epidermis contains no blood vessels, and its cells are nourished by diffusion from the underlying dermis. The bottom-most layer of the epidermis, called the stratum basale, is responsible for generating new skin cells that eventually move up to replace dead cells on the surface. This process of cell turnover takes about 28 days in adults.

The most superficial part of the epidermis consists of dead cells called squames, which are constantly shed and replaced. The exact rate at which this happens varies depending on location; for example, it's faster on the palms and soles than elsewhere. Melanocytes, the pigment-producing cells, are also located in the epidermis, specifically within the stratum basale layer.

In summary, the epidermis is a vital part of our integumentary system, providing not only physical protection but also playing a crucial role in immunity and sensory perception through touch receptors called Pacinian corpuscles.

Desmoglein 1 is a type of desmosomal cadherin, which is a transmembrane protein involved in cell-to-cell adhesion. It is primarily expressed in the upper layers of the epidermis and plays a crucial role in maintaining the integrity and stability of the skin. Desmoglein 1 forms desmosomes, specialized intercellular junctions that connect adjacent keratinocytes and help to resist shearing forces.

Desmoglein 1 is also a target for autoantibodies in certain blistering diseases, such as pemphigus foliaceus, where the binding of these antibodies to desmoglein 1 results in the loss of cell-to-cell adhesion and formation of skin blisters.

No FAQ available that match "netherton syndrome"

No images available that match "netherton syndrome"